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Abstract: Many researchers are developing nanocarriers in order to minimalize side effects 
of cytotoxic drugs during cancer treatment via chemotherapy. Nanocarriers can serve as a suitable 
platform for targeted drug delivery. To overcome their failure in in vivo use, the effects of surface 
modifications (PEGylation and PASylation) of natural nanocarriers based on apoferritin were tested 
in this work. Various properties of these modified apoferitin nanoparticles were studied, 
such as their size or degree of hemolysis. TEM characterization was also performed. The formation 
of hard coronas on these particles in plasma environment was evaluated using 
SDS-PAGE electrophoresis. The best biocompatibility results were obtained using apoferritin 
nanoparticles with PEG surface modification.
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INTRODUCTION 
Nowadays there are over 200 different types of cancer affecting humans (Broto et al. 2017)
Chemotherapy is a method for treating cancer using cytotoxic agents, whose main disadvantage 
is their non-specify for cancer cells. This means that they are also strongly affecting healthy cells. 
Thus, the actual dose of cytostatic received by affected tissue is hard to control (Broto et al. 2017).
By targeting of cytostatics directly to diseased tissue, it is possible to minimize the serious side effects 
of chemotherapy, such as the cardiotoxicity of doxorubicin or mutagenicity of ellipticine 
(Bazak et al. 2015). The number of nanocarriers that could be used for this purpose is growing 
exponentially, but only a few of these nanocarriers are currently tested in clinical trials and even lower 
number is used in clinical practice. To improve the success of their therapeutic use, 
a better understanding of their biological identity is needed. Many nanoconstructs cannot fulfil their
role after exposition to body environment; they can even lead to hemolysis or aggregation of blood 
platelets. Or, upon entering blood stream, nanoparticles are often coated by protein corona, changing 
their surface, and hampering their internalization into diseased cells. Protein corona forms after 
exposure of nanocarrier to plasma proteins that occur at 60-80 g/l (Broto et al. 2017). We can define 
protein corona as a natural interface between nanomaterials and living matter in biological milieu
(Monopoli et al. 2013).
In order to control and reduce the binding of additional biomolecules and formation of protein 
corona, surface modifications with various polymers can be used. In this contribution, we studied 
the effects of modification with poly-ethylene glycol (PEGylation) and peptides rich in proline, 
alanine and serine residues (PASylation). PEGylation represents chemical conjugation with synthetic 
hydrophilic and uncharged synthetic polymer PEG (Binder andSkerra 2017). This usually happens 
via the ε-amino group of lysine residues or the thiol group of cysteine. PEGylation is the most widely 
established method of prolonging the half-life of drug in bodily fluids (Pasut andVeronese 2012).
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To this date, there are up to 15 approved PEGylated drugs (Gabizon et al. 2016). The main drawbacks 
of using PEG for surface modification are its high cost, non-biodegradability and possible cellular 
vacuolation caused by PEG (Ivens et al. 2015). PASylation is a biological alternative to PEGylation 
based on genetic fusion or chemical coupling of nanoparticles with polypeptides (Chow et al. 2008).
PASylation bypasses disadvantages of PEGylation, such as its high cost and polydispersity. Moreover, 
PAS has lower viscosity and is more hydrophilic than PEG, which enables intravenous administration 
of PASylated drugs or nanoparticles (Binder and Skerra 2017). Their most important features 
are their non-immunogenicity (Harari et al. 2014), stability in plasma (Kuhn et al. 2016)
and quick degradation by intracellular/lysosomal proteases after cellular uptake, which does not cause 
cellular vacuolization (Binder and Skerra 2017).
The effects of PEGylation and PASylation on in vivo behaviour of nanoparticles were studied using 
ubiquitous protein cage apoferritin (Apo) with encapsulated ellipticine (Elli). Apo self-assembles 
into hollow rhombic dodecahedral cage of 12 nm in diameter, which stores and transports iron 
and iron ions in organism (Bulvik et al. 2012). Ellipticine is a natural pyridocarbazole type alkaloid 
showing cytotoxic activity against many cancer cell lines but it is highly mutagenic, which 
can be risky for healthy cells (Kizek et al. 2012). We encapsulated Elli into Apo and modified 
its surface with PEG or PAS sequences. The characterization of these nanoformulations 
was performed via dynamic light scattering (DLS) and transmission electron microscopy (TEM). 
The behaviour of these nanoparticles in human blood was evaluated using SDS-PAGE electrophoresis 
and hemolytic assay. 
MATERIAL AND METHODS
Chemicals
All chemicals of ACS purity were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Encapsulation of Elli into Apo
The stock solution of ellipticine with concentration of 1 mg/ml was prepared by dissolving Elli 
in 1 M HCl and deionized water in ratio 1 : 150. For each sample, 200 µl of 1 mg/ml Elli was added 
to 100 µl of deionized water and 20 µl of 50 mg/ml horse spleen Apo and gently mixed for 15 min. 
To reassemble the Apo structure disassembled by acidic Elli and encapsulate Elli in Apo cavity, 
0.66 µl of 1 M sodium hydroxide solution was added and the samples were mixed for further 15 min. 
To filter out non-encapsulated Elli, solution exchange was performed three times (centrifugation 
at 6000 g for 15 min).
Surface modification with PEG
50 µl of 10 mM PEG maleimide in PBS (phosphate buffered saline, pH 7.4: 0.137 M NaCl
+ 0.0027 M KCl + 0.0014 M KH2PO4 + 0.0043 M Na2HPO4) and 629 µl of PBS was added 
to ApoElli and mixed for 1 h. To filter unbound PEG, the sample was 5 times diafiltrated using 
Amicon® Ultra 0-5 ml 50K Merck Millipore (Billerica, MA, USA) at 6000 g for 15 min. 
Surface modification with PAS
25 µl of 1.3 nm gold nanoparticles was added to ApoElli and the samples were mixed 
for 14 h to allow binding of Au nanoparticles on the surface of ApoElli nanoparticles (creating 
ApoElli-Au). Solution exchange was performed two times to remove unbound Au nanoparticles. 
3 µl of 1.25 mg/ml PAS-10 (ASPAAPAPASC) and PAS-20 (ASPAAPAPASPAAPAPSAPAC)
was added to ApoElli-Au and the samples were incubated for 1 h at 45 °C to allow binding of cysteine 
to gold. Then, solution exchange was performed to remove unbound molecules of PAS peptides.
Characterization of prepared samples
Concentration of encapsulated Elli
The concentration of encapsulated Elli was evaluated by absorbance measurement
at 420 nm using Tecan Infinite 200 PRO (Männedorf, Switzerland).
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Size characterization by DLS 
The average size of prepared nanoparticles was determined by quasielastic dynamic light 
scattering using Zetasizer Nano ZS instrument, Malvern Instruments Ltd. (Worcestershire, UK). 
Polystyrene latex cells ZEN0040 were used for measurements and the conditions of measurements 
were as follows: detector angle of 173°, wavelength of 633 nm and temperature of 25 °C, equilibration 
time 120 s. The measurements were performed in hexaplicates.
TEM characterization
Visualization of nanocarriers and their surface modification was performed using transmission 
electron microscopy (TEM) with negative staining technique. An organotungsten compound Nano-W
Nanoprobes (Yaphank, NY, USA) was used. 4 μ of samples were deposited onto 400-mesh copper 
grids coated with a continuous carbon layer. Dried grids were imaged by TEM Tecnai F20; FEI, 
(Hillsboro, OR, USA).
In vitro evaluation of behaviour in human blood
Blood samples were collected into EDTA coated Vacutainer tubes and centrifuged at 3 000 rpm
and 25 °C for 10 min. Red blood cells (RBC) were used for hemolytic assay while pooled plasma was 
further centrifuged at 22 000 rcf and 4 °C and for 30 min and used to evaluate formation of protein 
corona.
Hard corona formation
100 µl of plasma was mixed with 100 µl of 200 µg/ml Elli, either free or encapsulated 
in modified and unmodified Apo nanocarrier. The samples were incubated at 600 rpm and 37 °C
for 35 min. To remove unbound plasma proteins from nanoparticles, 4 times solution exchange was 
performed. To determine the degree of protein corona formed on tested nanoformulations, SDS-PAGE 
electrophoresis was used. Proteins were separated at 200 V for 35 min using 12.5% polyacrylamide
gel.
Hemolysis assay
RBC were centrifuged at 3 000 rpm for 10 min multiple times and resuspended in 150 mM 
NaCl until the supernatants were transparent. Then, RBCs were diluted with PBS and 150 µl was 
mixed with 150 µl of decreasing concentrations of Elli (100; 50; 25; 12.5 and 6.3 µg/ml), either free 
or encapsulated in Apo nanoformulations; negative control (PBS) or positive control (0.2% Triton 
X-100). The samples were incubated at 37 °C and 600 rpm for 1 h. Incubation was followed 
by centrifugation at 3 000 rpm for 10 min. Absorbance at 540 nm was measured and the percentage 
of hemolysis was calculated via following formula:
                                           %hemolysis = [(At - Ac)/(A100% - Ac)] • 100                                   (1)
where At stands for absorbance of sample’s supernatant, Ac represents absorbance of negative control’s 
supernatant, A100% stands for absorbance of positive control’s supernatant.
RESULTS AND DISCUSSION
Characterization of prepared samples
Elli encapsulation efficiency, size characterization by DLS
The highest encapsulation efficiency (9%) was achieved in sample with PEG modification 
(Table 1). The size measurements (Table 1) showed that the size of Apo increased from 12 nm 
to 18 nm after encapsulation of Elli. The various surface modifications further influenced the size 
of ApoElli, where PAS-10 modification caused aggregation of multiple ApoElli molecules while 
PAS-20 and PEG modifications did not cause any aggregation.
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Table 1 Characterization of prepared nanoparticles
Sample Encapsulation efficiency
[%]























TEM characterization was performed to detect changes in apoferritin structure after surface 
modifications (Figure 1). The results showed that the tested surface modifications did not cause 
disassembly of Apo quaternary structure, as typical icosahedral particles were observed in all samples. 
The presence of polymer on ApoElli surface can be seen in PEGylated samples. PASylation 
was also proven by thicker protein shell of ApoElli. 
Figure 1 TEM images, scale corresponds to 25 nm (from left to right: apoferritin modified with PEG;
apoferritin modified with PAS-10; apoferritin modified with PAS-20; control without any surface 
modification)
Hemolysis assay



































To evaluate hemotoxicity of the tested nanoparticles, RBC hemolytic assay was performed. 
The results of hemolytic assay are summarized in Table 2. The lysed RBC caused red coloring 
of the supernatant, whereas transparent supernatant showed no occurring hemolysis. Free Elli caused 
hemolysis at all tested concentrations (see Figure 2) and the degree of hemolysis was dependent 
on Elli concentration (5% at 100 µg/ml). The encapsulation of Elli in Apo nanocarrier favorably 
influenced this hemolysis caused by Elli. Very low degree of hemolysis was observed only at highest 
Elli concentration in samples containing PEGylated ApoElli and sample without any surface 
modification (0.05% for PEGylated ApoElli and 0.06% for ApoElli). Samples with surface modified 
with PAS-10 (see Figure 3) and PAS-20 did not show any degree of hemolysis. The obtained results 
clearly show that all ApoElli nanoformulations, both unmodified and surface modified, are highly 
biocompatible with human RBC.
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Figure 2 Samples without using apoferritin nanocarrier (from left to right: negative control; 
6.25; 12.5; 25; 50 and 100 µg/ml Elli; positive control)
Figure 3 Samples modified with PAS-10 (from left to right: negative control; 6.25; 12.5; 25; 50 and 
100 µg/ml Elli encapsulated in Apo modified with PAS-10; positive control)
Evaluation of protein coronas
We further performed SDS-PAGE in order to evaluate the influence of PEGylation 
and PASylation on the formation of protein corona on ApoElli surface (see Figure 4). The ideal 
surface modification of nanocarrier should minimalize interactions between the surface of nanocarrier 
and plasma proteins, which naturally occur in human plasma. Efficient surface modification would 
reduce binding of proteins on the surface of nanocarrier, which leads to reduced protein corona 
formation or even inhibits protein corona formation all together. The surface modification 
with PAS-10 and PAS-20 did not decrease the interactions with plasma proteins and the protein 
corona was formed in a very similar way to that formed around unmodified ApoElli. 
Thus it can be concluded, that these modifications were not suitable for surface modifications 
of nanocarriers in order to avoid protein-nanocarrier interactions in bodily fluids. On the other hand, 
PEGylated ApoElli showed presence of no proteins from human plasma. Surface modification 
with PEG proved more suitable for future in vivo use as it was able to significantly lower 
protein-nanocarrier interactions.
Figure 4 SDS-PAGE (L - NEB Protein Ladder 10-250 kDa; 1 - PEGylated ApoElli; 2 - protein 
corona on PEGylated ApoElli; 3 - PAS-10ylated ApoElli; 4 - protein corona on PAS-10ylated 
ApoElli; 5 - PAS-20ylated ApoElli, 6 - protein corona on PAS-20ylated ApoElli; 7 - ApoElli; 
8 - protein corona on ApoElli)
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CONCLUSION 
The experiment presented in this work dealt with the prediction of in vivo behaviour 
of apoferritin nanocarrier, based on in vitro tests of their hemotoxicity and formation of protein corona 
around these particles in human plasma environment. The surface of this apoferritin nanocarrier was 
modified with polymer (PEG) and peptides (PAS) in order to decrease these negative interactions.
Overall, the results showed that while all tested modifications favourably influenced unwanted 
hemotoxicity of ellipticine, only PEGylation was able to lower interactions between nanocarrier 
surface and proteins in bodily fluids. 
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